- 한국 유방암학회 임상시험위원회 (KBCSG) / 등록사업위원회 위원
- 미국 임상 종양학회 (ASCO) / 유럽 종양내과 학회 (ESMO) 정회원
- 대한 외과학회 춘계학술대회 연구비 수상 (2022년)
- 세계 유방암 학술대회 (Global Breast Cancer Conference) 우수발표상 (2022년)
- 젊은 의사과학자 수상 (2020년)
- 유럽 종양내과학회 (ESMO) 학술대회 우수발표상 (2019년)
- 연세대학교 의과대학 대학원 우수논문상 (2014년)
최신 국제 저명 학술지 (SCI급 논문) 다수
1. Cha C, et al. Survival benefit from axillary surgery in patients aged 70 years or older with clinically node-negative breast cancer: A population-based propensity-score matched analysis. Eur J Surg Oncol. 2022; in press.
2. Cha C, et al. Impact of the ACOSOG Z0011 trial on surgical practice in Asian patients: trends in axillary surgery for breast cancer from a Korean Breast Cancer Registry analysis. World J Surg Oncol. 2022;20(1):198.
3. Cha C, et al. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer. Int J Cancer. 2021;149(8):1585-1592.
4. Lee J, Cha C, et al. Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index. Sci Rep. 2020;10(1):16850.
5. Cha C, et al. Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis. Breast Care (Basel). 2020;15(4):408-414.
6. Cha C, Lee J, Kim D, et al. Comparison of resection margin status after single or double radiopaque marker insertion for tumor localization in breast cancer patients receiving neoadjuvant chemotherapy. Breast Cancer Res Treat. 2020;184(3):797-803.
7.Cha C, Ahn SG, Lee HM, Lee HW, Lee SA, Jeong J. Assessment of adjuvant trastuzumab-associated cardiac toxicity in korean patients with breast cancer: a single-center analysis. Oncology. 2013;85(4):228-234.